Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer

about

Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer

Item

http://www.wikidata.org/entity/Q36494555

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer

@ast

Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer

@en

type

Item

label

Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer

@ast

Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer

@en

prefLabel

Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer

@ast

Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer

@en

P1476

Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer

@en

P2093

Elżbieta Łuczyńska

http://www.w3.org/2001/XMLSchema#string

Jerzy W Mituś

http://www.w3.org/2001/XMLSchema#string

Marek Jasiówka

http://www.w3.org/2001/XMLSchema#string

Wiktor Szatkowski

http://www.w3.org/2001/XMLSchema#string

P2860

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival.

Nonparametric Estimation from Incomplete Observations

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.

Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations.

A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer.

Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.

Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy.

CA125 as a serum marker for poor prognosis in ovarian malignancies.

P2888

s13053-015-0041-2

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13053-015-0041-2

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Tomasz Byrski

Pawel Blecharz

Jerzy Jakubowicz

P577

2016-01-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

291690296

http://www.w3.org/2001/XMLSchema#string

P6179

1041821505

http://www.w3.org/2001/XMLSchema#string

P698

26807161

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

4724399

http://www.w3.org/2001/XMLSchema#string